06:59 EDT Biogen (BIIB) to acquire Apellis (APLS) for $41.00 per share in cash at closing, or $5.6B
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen: Spinraza HD Approval Supports but Does Not Transform Outlook; Leqembi Execution and MS Erosion Keep Rating at Hold
- Biogen: Incremental Pipeline Progress and Spinraza Update Support Hold Rating Amid Ongoing Uncertainties
- High-dose Spinraza approval, AMETHYST data drivers for Biogen, says BMO Capital
- Biogen announces FDA approval of high dose regimen of Spinraza
- Biogen (Litifilimab/Lupus): Encouraging Early Data but Competitive and Clinical Risks Support a Neutral Hold